S&P Futures
3,914.50 +10.75 (+0.28%) Dow Futures
31,526.00 +105.00 (+0.33%) Nasdaq Futures
12,067.25 +26.75 (+0.22%) Russell 2000 Futures
1,777.80 +8.00 (+0.45%) Crude Oil
111.03 +1.46 (+1.33%) Gold
1,827.90 +3.10 (+0.17%)
Hillstream BioPharma, Inc. (HILS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7559 |
| Open | 1.0800 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.8700 - 1.1200 |
| 52 Week Range | 0.6500 - 4.2400 |
| Volume | |
| Avg. Volume | 1,435,893 |
| Market Cap | 10.328M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3910 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HILS
Related Research
- Hillstream BioPharma, Inc.Technical Assessment: Bearish in the Intermediate-TermWe have not talked much about small-cap stocks as they have steadily underperformed the S&P 500 since February 2021 and the S&P MidCap 400 since January 2021. Both the Russell 2000 (IWM) and the S&P SmallCap 600 (SML) peaked in November 2021 and have been tracing out lower lows and lower highs ever since. At the June 16 closing low, the IWM had cratered 32% while the SML had given up 26%. Interestingly, the hyper-revenue-growth/no-EPS stocks peaked in late 2020 and early 2021, well before the small-caps. The Nasdaq, QQQs and the S&P 500 all peaked in late 2021/early 2022.RatingFair ValueEconomic Moat4 days agoArgus Research
- GlobeNewswire
Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments
Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint InhibitorsBRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced a collaboration with Sapien Biosciences to evaluat
- Benzinga
Why Hillstream BioPharma Shares Are Trading Higher Today?
Hillstream BioPharma Inc (NASDAQ: HILS) shares are trading higher after it authorized a share repurchase program to acquire up to $1 million in common stock. As of March 31, Hillstream had approximately $11.1 million in cash and 11.4 million shares of common stock. "We have demonstrated strong execution and, as a result, have seen significant advancement of our pipeline," said Randy Milby, Hillstream's CEO. "The current market situation allows us to capture additional value for all investors thr
- GlobeNewswire
Hillstream BioPharma Announces Share Repurchase Program
BRIDGEWATER, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced that its Board of Directors has authorized a share repurchase program to acquire up to $1 million of the Company's common stock. The Company may purcha
